S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
TSE:AKU

Akumin (AKU) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
C$0.40
C$0.53
52-Week Range
N/A
Volume
12,902 shs
Average Volume
7,202 shs
Market Capitalization
C$37.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AKU stock logo

About Akumin Stock (TSE:AKU)

Akumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida. On October 22, 2023, Akumin Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

AKU Stock News Headlines

TSX Health Care Sector
Akumin Inc. (AKU.TO)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Akumin Announces Changes to Leadership Team
AKUMIN ANNOUNCES LEADERSHIP TRANSITION
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Akumin Inc Ordinary Shares
Crude Oil Falls Sharply; Apollomics Shares Plunge
Why Is Akumin (AKU) Stock Up 31% Today?
Closing Bell: Akumin Inc down on Friday (AKU)
Glassbeam appoints Rhonda Longmore-Grund as Chairman
Closing Bell: Akumin Inc up on Monday (AKU)
Closing Bell: Akumin Inc down on Monday (AKU)
See More Headlines
Receive AKU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akumin and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,527
Year Founded
N/A

Profitability

Net Income
C$-255,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$737.69 million
Book Value
C($2.86) per share

Miscellaneous

Free Float
N/A
Market Cap
C$37.20 million
Optionable
Not Optionable
Beta
0.15
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Riadh Zine-El-Abidine (Age 52)
    Chairman & CEO
    Comp: $2.4M
  • Mr. Krishna Kumar Ananthasubramanian
    President & COO
  • Mr. Ronald J. Bienias (Age 52)
    Interim CFO & Chief Restructuring Officer
  • Mr. Paul Nelis (Age 56)
    Chief Information Officer
  • Darren Speed
    Chief Compliance Officer
  • Ms. Tracy Wiese (Age 55)
    Chief Strategy & Marketing Officer
  • Ms. Holly Huso (Age 59)
    Enterprise Sales Officer
  • Ms. Laurie R. Miller (Age 57)
    Chief Human Resources Officer
  • Mr. Mohammad Saleem
    Senior Vice President of Financial Reporting
  • Mr. Christopher Fitzgerald
    Chief Revenue Officer

AKU Stock Analysis - Frequently Asked Questions

Should I buy or sell Akumin stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akumin in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AKU shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKU, but not buy additional shares or sell existing shares.
View AKU analyst ratings
or view top-rated stocks.

What other stocks do shareholders of Akumin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akumin investors own include AltaGas (ALA), Alimentation Couche-Tard (ATD.B), Brookfield Property Partners (BPY.UN), Cargojet (CJT), Canadian National Railway (CNR), Dollarama (DOL), Enbridge (ENB), Héroux-Devtek (HRX) and Inter Pipeline (IPL).

How do I buy shares of Akumin?

Shares of AKU stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:AKU) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners